Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heerak Kang

Pain Medicine Las Vegas, NV Medical Doctor

NPI 1871026518 CMS profile 11260559

9327 W Sunset Rd, Las Vegas, NV 89148

Open in the dashboard

General payments

$10,763

69 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heerak Kang of Las Vegas, NV is reported in the CMS Open Payments database as having received $10,763 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,399 23
2024 General $206 3
2023 General $72 2
2022 General $4,674 28
2021 General $1,413 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heerak Kang
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Heerak Kang were reported at $4,399. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Heerak Kang Pain Medicine median Middle half National median
2019 $0 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $1,413 $452 $134–$1,237 $132
2022 $4,674 $475 $124–$1,407 $149
2023 $72 $480 $136–$1,384 $160
2024 $206 $521 $164–$1,511 $164
2025 $4,399 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $3,931 25 payments
  2. Boston Scientific Corporation $2,894 19 payments
  3. Saluda Medical Americas, Inc. $2,230 7 payments
  4. Nevro Corp. $720 2 payments
  5. SPR Therapeutics, Inc $519 7 payments
  6. Medtronic, Inc. $417 7 payments
  7. SI-BONE, Inc. $30 1 payment
  8. Curonix LLC $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $6,742 19 payments
  2. Food and Beverage $3,304 49 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $717 1 payment
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $2,244 14 payments
  2. Evoke $2,230 7 payments
  3. PROCLAIM Neuromodulation $1,612 10 payments
  4. General - Therapies $1,274 5 payments
  5. Omnia $720 2 payments
  6. SPECTRA WAVEWRITER $641 5 payments
  7. SPRINT PNS System $519 7 payments
  8. WaveWriter Alpha Prime 16 $421 6 payments
  9. WAVEWRITER ALPHA $390 2 payments
  10. RESTORE $352 4 payments
  11. Other $331 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

699

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$8,777

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

2.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 277 $3,878
Celecoxib Generic 31 $1,728
Pregabalin Generic 52 $901
Duloxetine Hcl Generic 83 $822
Baclofen Generic 24 $411
Cyclobenzaprine Hcl Generic 56 $382
Tizanidine Hcl Generic 21 $128
Meloxicam Generic 56 $113
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $112
Amitriptyline Hcl Generic 26 $108

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$93,550

Medicare's payments for the services billed

Medicare patients

290

Average age 73

Services billed

1,057

183 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Diabetes 29%
Depression 27%
Ischemic heart disease 24%
Osteoporosis 21%
Chronic kidney disease 20%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record